Related references
Note: Only part of the references are listed.Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
Anthony B. El-Khoueiry et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC).
Mario Sznol et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety of Infusing Ipilimumab Over 30 Minutes
Parisa Momtaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
Giuliana Carlos et al.
MELANOMA RESEARCH (2015)
Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer
Aaron I. Loochtan et al.
MUSCLE & NERVE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy
Mizuki Nishino et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Toxicity Patterns With Immunomodulating Antibodies and Their Combinations
John B. A. G. Haanen et al.
SEMINARS IN ONCOLOGY (2015)
Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
Rita E. Morales et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
Richard W. Joseph et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient
Steven P. Merrill et al.
ANNALS OF PHARMACOTHERAPY (2014)
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
Magnus Pedersen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder et al.
ENDOCRINE-RELATED CANCER (2014)
Kidney injuries related to ipilimumab
Hassane Izzedine et al.
INVESTIGATIONAL NEW DRUGS (2014)
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Oriana Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin et al.
LANCET ONCOLOGY (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
Bing Liao et al.
NEURO-ONCOLOGY (2014)
Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms
G. Garrido et al.
ONCOGENE (2014)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann Kyi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Combinations of immunotherapy and radiation in cancer therapy
Ralph E. Vatner et al.
FRONTIERS IN ONCOLOGY (2014)
Ipilimumab Granulomatous Interstitial Nephritis
Bijin Thajudeen et al.
AMERICAN JOURNAL OF THERAPEUTICS (2013)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
Patterns of Onset and Resolution of Immune-Related Adverse Events of Special Interest With Ipilimumab Detailed Safety Analysis From a Phase 3 Trial in Patients With Advanced Melanoma
Jeffrey S. Weber et al.
CANCER (2013)
Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
Igor Z. Barjaktarevic et al.
CHEST (2013)
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kyung Won Kim et al.
INVESTIGATIONAL NEW DRUGS (2013)
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Salvatore Maria Corsello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
Sebastian G. Bernardo et al.
MELANOMA RESEARCH (2013)
Ipilimumab-induced acute severe colitis treated by infliximab
Cecile Pages et al.
MELANOMA RESEARCH (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
David E. Kleiner et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review
Agata Juszczak et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis
T. Krenacs et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2012)
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Gregoire Berthod et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
S. Wilgenhof et al.
ANNALS OF ONCOLOGY (2011)
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Le Min et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
Katarzyna D. Chmiel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Gary Borodic et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
J. Rafael Sierra et al.
MOLECULAR CANCER (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
Kim L. Good-Jacobson et al.
NATURE IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunogenic death of colon cancer cells treated with oxaliplatin
A. Tesniere et al.
ONCOGENE (2010)
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
Troy Dillard et al.
PITUITARY (2010)
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment
G-One Ahn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The Emerging Toxicity Profiles of Anti-CTLA-4 Antibodies Across Clinical Indications
Anna Maria Di Giacomo et al.
SEMINARS IN ONCOLOGY (2010)
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
David R. Minor et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma A Case Report
Shailender Bhatia et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Genetics of Type 1A Diabetes.
Vincenzo Sepe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer
Christina L. Roland et al.
PLOS ONE (2009)
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
Elizabeth A. Manning et al.
CLINICAL CANCER RESEARCH (2007)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
JA Blansfield et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor
AA Lugade et al.
JOURNAL OF IMMUNOLOGY (2005)
Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming
A Merrick et al.
BRITISH JOURNAL OF CANCER (2005)
Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells
YP Liao et al.
JOURNAL OF IMMUNOLOGY (2004)
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma - A new cause of uveitis
MR Robinson et al.
JOURNAL OF IMMUNOTHERAPY (2004)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis
HB Wang et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
